Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Dasatinib response in AML

Nathali Kaushansky, PhD, Weizmann Institute of Science, Rehovot, Israel, outlines the study which aimed to predict in vitro response to targeted therapies, based on molecular markers, with subsequent validation in leukemic stem cells. Results showed that dasatinib response in acute myeloid leukemia (AML) is correlated with FLT3/ITD, PTN11 mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).